bioRxivGeneticsPreprint
Altered chromatin accessibility and nucleosome positioning landscape upon HDAC and LSD1 inhibition in cancer cell
Sagnik SeniD, Pierre Olivier EsteveiD, Devesh Tarasia, Rachel Danneberg, Ashmita DeyiD, Ujjwal MaulikiD, Sanghamitra BandyopadhyayiD, Sriharsa PradhaniD
- Citations
- 1
Abstract
Epigenetic enzymes, writers, readers and erasers regulate chromatin landscapes and participate in tumor heterogeneity. While therapeutic targeting of these enzymes has shown clinical promise, the comparative efficacy of mono-versus dual-inhibitor strategies remain unclear. Here, we introduce a multi-modal platform that uses NicE-viewSeq and integrates automated deep learning based spatially resolved chromatin accessibility profiling with high-throughput sequencing following epigenetic inhibitor application. Accessible chromatin landscapes were altered along with nucleosome positioning following inhibition of either LSD1 or HDACs alone, or both together. Coordinated modulation of histone marks and the CoREST complex on chromatin was observed across inhibitory conditions. Transcription factor binding analysis identified three predominant families, ETS, RUNT, and bZIP with enhanced chromatin association upon treatments. Mechanistically, a CoREST-RUNX regulatory axis was uncovered wherein JunB, a member of bZIP family displaces CoREST-RUNX at differentially accessible regions, triggering apoptotic pathways. Therefore, JunB-mediated mechanism reveals a convergent therapeutic vulnerability, offering new avenues for optimizing different combinatorial epigenetic therapy in cancer.
- organism: human
- assay: ChIP-seq
- assay: Hi-C
- research focus: gene regulatory network inference
- research focus: differential expression
- approach: deep learning
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epigenomic manipulation reveals the relationship between locus specific chromatin dynamics and gene expression
Vrinda Venu, Eric M. Small, … Christina R. Steadman·Epigenetics & ChromatinPeer-reviewed·Oct 3, 2025
- A network of epigenomic and transcriptional cooperation encompassing an epigenomic master regulator in cancer
Stephen P. Wilson, Fabian V. Filipp·npj Systems Biology and ApplicationsPeer-reviewed·Jun 7, 2018
- Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers
Mohamad Ali Toufic Najia, Deepak Kumar Jha, … George Q. Daley·bioRxiv·Jan 31, 2025
- EZH1-dependent H3K27me1 is an adaptive chromatin barrier that limits DNMT inhibitor response in colorectal cancer
Alison A. Chomiak, Ashley K. Wiseman, … Scott B. Rothbart·bioRxiv·Sep 16, 2025
- Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs
Tomás Alarcón, Josep Sardanyés A, … Javier Abel Menéndez·PLoS Computational BiologyPeer-reviewed·Jun 21, 2021
- Chemical perturbations impacting histone acetylation governcolorectal cancer differentiation
Pornlada Likasitwatanakul, Zhixin Li, … Nilay S. Sethi·GastroenterologyPeer-reviewed·Jul 7, 2025